HLA-DRB1 is part of the HLA class II beta chain paralogs. The class II molecule is a heterodimer composed of an alpha (DRA) and a beta chain (DRB), both of which are anchored in the membrane. This molecule is crucial in the immune system as it presents peptides from extracellular proteins. Class II molecules are expressed on antigen-presenting cells. The beta chain, approximately 26-28 kDa, is encoded by six exons. Exon one encodes the leader peptide; exons two and three encode the two extracellular domains; exon four encodes the transmembrane domain; and exon five encodes the cytoplasmic tail. The beta chain contains all polymorphisms that determine peptide binding specificities. Hundreds of DRB1 alleles exist, some of which are associated with certain diseases. For instance, DRB1*1302 is associated with the persistence of acute and chronic hepatitis B virus infection. Additionally, this gene has multiple pseudogenes.

Gene and Protein Complex Functionality

HLA-DRB1 facilitates several functions, including MHC class II receptor activity, peptide antigen binding, and signaling receptor binding. It is involved in processes such as the positive regulation of immune response, gene expression regulation, and leukocyte differentiation. This gene’s products are located in the bounding membrane of organelles, on the external side of the plasma membrane, and within the immunological synapse. HLA-DRB1 is part of the MHC class II protein complex and is implicated in various diseases, including asthma, autoimmune diseases, bacterial infectious diseases, eye diseases, and sarcoidosis. It also serves as a biomarker for toxic shock syndrome.

Detailed Function and Structure

The HLA-DRB1 gene encodes a protein essential to the immune system. It is part of the human leukocyte antigen (HLA) complex, which helps the immune system differentiate between the body’s proteins and those of foreign invaders, such as viruses and bacteria. The HLA complex is the human equivalent of the major histocompatibility complex (MHC) found in many species. HLA-DRB1 belongs to the MHC class II group, which encodes cell-surface proteins. These proteins bind to extracellular peptides and display them to the immune system, prompting a response if they are identified as foreign.

The beta chain produced by HLA-DRB1 binds to the alpha chain produced by HLA-DRA, forming the HLA-DR antigen-binding heterodimer. This complex displays foreign peptides to the immune system, triggering an immune response. Each MHC class II gene has numerous variations, enabling the immune system to respond to various foreign invaders. Researchers have identified hundreds of HLA-DRB1 alleles, each designated by a unique number (e.g., HLA-DRB1*04:01).

Allele DRB1*01:01

• Bacillus anthracis pagA/protective antigen, PA: KLPLYISNPNYKVNVYAVT
• HIV-1 gag peptide: FRDYVDRFYKTLRAEQASQE
• HRV-16 capsid proteins:
  • VP1: PRFSLPFLSIASAYYMFYDG
  • VP2: PHQFINLRSNNSATLIVPYV
• IAV external protein HA:
  • PKYVKQNTLKLAT
  • SNGNFIAPEYAYKIVK
• IAV internal proteins M, NP, and PB1:
  • M-derived epitope: GLIYNRMGAVTTEV
• COL4A3: GWISLWKGFSF
• MBP: VHFFKNIVTPRTP

Allele DRB1*03:01

• HRV-16 capsid protein VP2: NEKQPSDDNWLNFDGTLLGN
• Retinal SAG: NRERRGIALDGKIKHE
• Thyroid TG: LSSVVVDPSIRHFDV
• HHV-6B gH/U48 and U85 antigens (no specific peptide sequences provided)
• C. tetani neurotoxin tetX (no specific peptide sequences provided)

Allele DRB1*04:01

• M. tuberculosis esxB/culture filtrate antigen CFP-10: EISTNIRQAGVQYSR
• HRV-16 capsid protein VP2: NEKQPSDDNWLNFDGTLLGN
• Melanoma-associated TYR antigen:
  • QNILLSNAPLGPQFP
  • DYSYLQDSDPDSFQD
• VIM:
  • GVYATR/citSSAVR
  • SAVRAR/citSSVPGVR
• ACAN: VVLLVATEGR/CitVRVNSAYQDK
• COL2A1 (no specific peptide sequences provided)

Allele DRB1*04:02

• VIM: Native or citrullinated self-peptides (no specific sequences provided)

Allele DRB1*04:04

• HRV-16 capsid proteins:
  • VP1: HIVMQYMYVPPGAPIPTTRN
  • VP2: RGDSTITSQDVANAVVGYGV
• VIM: SAVRAR/citSSVPGVR

Allele DRB1*04:05

• Tumor-associated antigen WT1: KRYFKLSHLQMHSRKH

Allele DRB1*05:01

• HIV-1 gag peptide: FRDYVDRFYKTLRAEQASQE

Allele DRB1*07:01

• EBV latent antigen EBNA2 peptide: PRSPTVFYNIPPMPLPPSQL
• HRV-16 capsid proteins:
  • VP1: PRFSLPFLSIASAYYMFYDG
  • VP2: VPYVNAVPMDSMVRHNNWSL
• Tumor-associated antigen WT1: MTEYKLVVVGAVGVGKSALTIQLI
• KRAS neoantigen: MTEYKLVVVGAVGVGKSALTIQLI (G12V mutation)

Allele DRB1*11:01

• HIV-1 gag peptide: FRDYVDRFYKTLRAEQASQE
• HRV-16 capsid protein VP2: SDRIIQITRGDSTITSQDVA
• C. tetani neurotoxin tetX (no specific peptide sequences provided)

Allele DRB1*13:01

• HHV-6B antigens (no specific peptide sequences provided)

Allele DRB1*15:01

• HRV-16 capsid protein VP2: SNNSATLIVPYVNAVPMDSM
• MBP: ENPVVHFFKNIVTPR
• Tumor-associated antigen WT1: KRYFKLSHLQMHSRKH

Allele DRB1*15:02

• HIV-1 gag peptide: FRDYVDRFYKTLRAEQASQE
• Tumor-associated antigen WT1: KRYFKLSHLQMHSRKH

This linear peptide is suggested: MTEYKLVVVGAVGVGKSALTIQLI

A study utilized a rapid, high-throughput approach to experimentally measure peptide/HLA thermal stability on a scale needed for analyzing neoantigens from thousands of patients. By combining UV-cleavable peptide/HLA class I complexes with differential scanning fluorimetry, the Tm values of neoantigen complexes were determined. These Tm values were accurate, reproducible, and directly proportional to the complexes’ half-lives. When analyzing known HLA-A2–restricted immunogenic peptides, Tm values correlated more strongly with immunogenicity than algorithm-predicted binding affinities. Using temperature stability information can help select neoantigens for cancer vaccines, focusing on mutated peptides most likely to be expressed on the cell surface.

Tm analysis of HLA-A2 complexes containing immunogenic neoantigen peptides

Poly(ethylene glycol) (PEG), also known as poly(ethylene oxide) (PEO), has long been the polymer of choice in biomedicine, widely recognized for its ability to extend the half-life and reduce the immunogenicity of proteins. While PEG’s biocompatibility, low dispersity, and immune evasion have established it as a standard in biomedicine, it is not without its shortcomings. Notably, the prevalence of anti-PEG antibodies in patients poses a potential hindrance, as does the polyether backbone’s vulnerability to oxidative degradation.

Check LifeTein’s Pegylation Service!

This is where Poly(2-alkyl/aryl-2-oxazoline)s, abbreviated as PAOx, POx, or POZ, step in, offering a promising alternative with higher stability and tunability than PEG. PAOx polymers maintain the critical properties required for biomedical use, such as biocompatibility and “stealth” behavior, but with enhanced functionalization options. The synthesis of PAOx via cationic ring-opening polymerization (CROP) yields polymers with a tertiary amide backbone that interacts minimally with proteins and is largely ignored by the immune system.

PAOx can be tailored at the molecular level to adjust the hydrophilic-hydrophobic balance and control the lower critical solution temperature (LCST), enabling a fine-tuning of physical properties for a range of applications. Notably, some PAOx variants exhibit thermoresponsive behavior, becoming more hydrophobic at higher temperatures—a property leveraged in innovative material design for applications like diagnostics and triggered drug release.

The similarity of PAOx structures to natural polypeptides accounts for their biocompatibility and stealth behavior. Studies demonstrate that PAOx-based pharmaceuticals exhibit rapid clearance from the bloodstream and minimal accumulation in the reticuloendothelial system, suggesting a favorable toxicity profile and a promising future in human clinical applications.

The extensive applications of PAOx in drug delivery are diverse and inventive. PAOx can significantly improve drug solubility and bioavailability as excipients in drug formulations. PAOx-based micellar systems exploit the polymer’s amphiphilic nature to achieve high drug loading, which is especially beneficial for cancer therapeutics with low water solubility. Additionally, PAOx-based hydrogels provide versatile platforms for drug delivery and tissue engineering, with potential for injectable applications and for customization through polymer chain functionalization.

The conjugation of drugs and proteins with PAOx—referred to as PAOxylation—has yielded conjugates that often outperform their PEGylated equivalents. For example, PAOx-protein conjugates have demonstrated prolonged efficacy compared to non-conjugated forms and increased cellular uptake.

Advances in PAOx research are ongoing, and applications are expanding to include nanoparticle functionalization. These PAOx-functionalized nanoparticles possess unique characteristics beneficial for imaging and drug delivery, and are “smart” materials that respond to external stimuli.

Given the breadth of possibilities that PAOx polymers offer, the biomedical field stands on the cusp of a new era in which drug delivery and patient care may be significantly enhanced through these versatile materials. With ongoing research and clinical trials, the potential for PAOx to become a leading platform in precision medicine and beyond is becoming increasingly apparent.

Peptide-protein interactions are characterized by the binding of peptides to large, often shallow pockets on protein surfaces without significantly altering the protein conformation. These interactions are typically stabilized by hydrogen bonds and interactions with key residues, enriching the interface with hydrophobic and aromatic residues reminiscent of the protein’s core (LifeTein Peptide). This understanding is crucial for designing peptide-based inhibitors that can precisely target and modulate specific PPIs, offering a strategic approach to drug development.

The design of peptide-based inhibitors often involves identifying and targeting conserved protein domains that recognize short linear peptide motifs. This approach benefits from the structural diversity and flexibility of peptides, allowing them to adopt various conformations for optimal binding. Domains such as SH2, PTB, SH3, and WW domains recognize specific motifs, offering a blueprint for designing peptides that can interfere with these interactions. Despite the challenge posed by the similarity between recognized sequences, structural insights into protein-peptide interactions have facilitated the development of selective peptide drugs.

The advancement in computational tools and structural biology has significantly impacted the design of protein-targeting peptides. Increased availability of crystallographic structures of protein complexes has paved the way for rational drug design, enabling the identification of crucial interaction sites and the development of peptides that can target these sites to modulate biological pathways effectively. Combinatorial approaches, such as phage display, peptide arrays, and peptide aptamers, complement rational design by identifying high-affinity peptide sequences through screening.

Furthermore, the self-assembly and molecular recognition properties of peptides extend their application beyond drug development to the creation of supramolecular biomaterials. These materials harness the self-organizing capacity of peptides to form structures that can interact with biological systems in a controlled manner, opening new avenues for drug delivery, tissue engineering, and the development of novel therapeutics (MDPI).

In the context of cancer research, peptides targeting PPIs present a promising strategy for developing novel therapeutic agents. The modulation of PPIs involved in oncogenic pathways, tumor suppression, and immune evasion mechanisms can provide targeted interventions with potentially high specificity and lower toxicity compared to conventional chemotherapy. The continuous improvement of computational and experimental methodologies is expected to enhance further the discovery and development of peptide-based PPI modulators with optimal properties for clinical application (Frontiers in Science).

Overall, the field of peptide-mediated modulation of protein-protein interactions is rapidly advancing, offering promising strategies for therapeutic development against a wide range of pathologies, including cancer. The synergy between computational design, structural biology, and experimental screening methods is critical to unlocking the full therapeutic potential of peptides in targeting complex biological interactions.

Generally, two main approaches to generating labeled peptides are synthesizing the peptide with labeled amino acids incorporated or adding the label post-synthesis. Incorporating labeled amino acids during synthesis is typically preferred, as it ensures the label is positioned correctly within the peptide structure. However, challenges may arise, such as issues with the solubility of the peptide epitopes, especially for longer sequences​ (LifeTein)​.

A specific example of this strategy’s application is the synthesis of peptides with a C-terminal biotin-labeled lysine. In one approach, a peptide was synthesized on Rink amide MBHA resin coupled with Fmoc-Lys(Dde)-OH, allowing for subsequent labeling of the peptide’s side chain. This technique ensures the label, such as biotin, is precisely added to a designated site on the peptide, following peptide synthesis and prior to its cleavage from the resin​ (LifeTein)​.

This approach exemplifies the versatility and efficacy of using solid-phase peptide synthesis (SPPS) for creating specifically labeled peptides for various research purposes. By selecting appropriate protecting groups and resin, researchers can streamline the synthesis of peptides with desired labels, enhancing their utility in biological studies​ (LifeTein)​.

For more detailed insights into this peptide synthesis strategy’s process and potential applications, visiting sources such as LifeTein’s overview on peptide synthesis could provide valuable information and guidance​ (LifeTein)​.

SPPS is often the method of choice for creating MAPs due to its efficiency and cost-effectiveness. The process involves the sequential addition of amino acids to a branched poly-lysine core, each branch potentially representing a different epitope. While this approach is less time-consuming and generally more cost-effective than conjugation methods, it is not without its challenges. The complexity of MAPs can lead to synthesis errors, resulting in microheterogeneity within the final product. Additionally, the solubility of peptide epitopes in MAP constructs can be unpredictable, particularly for longer sequences, which may affect the overall success of the synthesis.

The incorporation of an aminohexanoic acid (Ahx) linker into the lysine core of MAPs has been shown to improve yield, likely due to the increased solubility and reduced aggregation it offers during synthesis. These properties are essential for maintaining the solubility of growing peptide chains, thus enhancing the efficiency of MAP synthesis.

MAPs have broad applications in studying peptide-protein interactions, which are crucial for understanding cellular processes. Protein-peptide interactions, which constitute a significant portion of cellular interactions, can be explored using MAPs designed with various features to improve their interaction with target proteins. Strategies for enhancing the efficacy of MAPs include analyzing charged residues to improve solubility, using control peptides (such as scrambled sequences) for comparison, incorporating cell-penetrating peptides (CPPs) like the TAT sequence for enhanced cell entry, and adding spacers or linkers to increase molecular flexibility. Additionally, the use of D-amino acids can help avoid peptide degradation, and biotin conjugation allows for the facile pull-down of target proteins.

In summary, MAPs represent a powerful tool in the toolkit of molecular biologists and immunologists, facilitating detailed studies of immune responses and peptide-protein interactions. By leveraging MAPs’ unique advantages, including their ability to present multiple epitopes and enhance immunogenic responses, researchers can gain deeper insights into protein functions and interactions, vaccine development, and therapeutic peptide design. However, the successful application of MAPs requires careful consideration of their synthesis, solubility, and design to overcome potential limitations and achieve desired outcomes in scientific research.

However, DMSO’s application extends beyond cryopreservation, especially in dissolving hydrophobic peptides, which can be challenging to solubilize in aqueous solutions due to their inherent properties. The introduction of DMSO can enhance cell permeability, making it a valuable tool for delivering such peptides into cells. Yet, caution is necessary as DMSO concentrations exceeding 0.5% might induce cytotoxic effects, jeopardizing cell viability. While most cell lines can endure up to 0.5% DMSO with minimal cytotoxicity, primary cells often require even lower concentrations, not exceeding 0.1%, to avoid adverse effects​ (LifeTein)​.

To safely introduce peptides dissolved in DMSO into cell culture:

1. Dissolve peptides in a minimal volume of DMSO, aiming for a concentration that allows for further dilution in the cell culture medium.
2. Dilute the DMSO-peptide solution gradually in an aqueous buffer solution, such as PBS, to achieve the desired final peptide concentration in the cell culture. Vigilance is needed to prevent the solution from becoming turbid, indicating solubility limits have been reached. Sonication might aid in dissolving the peptides further​ (LifeTein)​.
3. Final concentration adjustment is crucial, ensuring that DMSO does not exceed safe levels for the cell type in culture. Keeping the final DMSO concentration around 0.1% is advisable to ensure compatibility with almost all cell lines. Up to 0.5% can be employed for applications necessitating higher DMSO concentrations, provided cell viability is not compromised​ (LifeTein)​.

By adhering to these guidelines, researchers can leverage DMSO’s solubilizing properties for hydrophobic peptides while minimizing potential cytotoxic effects on cell cultures. Including controls treated with DMSO alone in experiments is essential to discern any DMSO-related impacts from those of the peptide of interest. This balanced approach allows the exploration of peptide functions in cellular contexts without compromising cell health and experiment integrity.

In the field of peptide synthesis, linkers play a crucial role by bridging the gap between various molecular entities, thus enabling the creation of complex peptides and proteins with desired functionalities. These linkers are not merely inert spacers; they are carefully selected to impart stability, solubility, and specificity to the resultant molecules. Among the plethora of linkers used, Fmoc-NH-PEG (Polyethylene glycol) derivatives and Aminohexanoic Acid are particularly noteworthy due to their unique properties and applications in both synthetic chemistry and biological studies.

Fmoc-NH-PEG derivatives, such as Fmoc-NH-PEG2-CH2COOH and Fmoc-NH-PEG3-CH2CH2COOH, are widely utilized in peptide synthesis for several reasons. The Fmoc (9-Fluorenylmethyloxycarbonyl) group serves as a temporary protector for amino groups, facilitating the sequential addition of amino acids in a controlled manner. The PEG (Polyethylene glycol) segment, varying in length (e.g., PEG2, PEG3), introduces solubility and flexibility into the peptide chain. This solubility is critical for otherwise insoluble peptides in aqueous or organic solvents, limiting their biological application. Moreover, the flexibility provided by the PEG linker is beneficial for peptides required to adopt specific conformations for binding to proteins or other targets in biological systems.

Aminohexanoic Acid, a simpler linker, offers a hydrophobic chain that can increase the peptide’s overall hydrophobicity, influencing its interaction with biological membranes and other hydrophobic entities within the cell. This property is precious in the delivery of therapeutic peptides, where membrane permeability is a crucial factor.

The application of these linkers extends beyond mere synthesis. In biological studies, they facilitate the exploration of protein-protein interactions, enzyme-substrate relationships, and the mechanisms of action of therapeutic peptides. For instance, a peptide linked with a PEG spacer can be used to probe the active site of an enzyme without undue steric hindrance, enabling researchers to glean insights into enzyme kinetics and substrate specificity. Similarly, in protein function and structure studies, these linkers allow the attachment of fluorescent tags or other probes to peptides without significantly altering their native structure or function, thus enabling real-time tracking of peptide behavior in live cells or in vitro systems.

Furthermore, in therapeutic applications, the use of such linkers can dramatically improve the pharmacokinetic and pharmacodynamic profiles of peptide drugs. By enhancing solubility, reducing degradation by proteases, and modulating interaction with biological targets, these linkers contribute to the efficacy and safety of peptide-based therapies.

In summary, linkers like Fmoc-NH-PEG derivatives and Aminohexanoic Acid are indispensable tools in peptide synthesis and have broad implications in biological research and therapeutic development. Their ability to confer solubility, flexibility, and specific physicochemical properties to peptides opens up vast possibilities for studying and manipulating biological systems at the molecular level. As our understanding of these linkers and their interactions within complex biological matrices deepens, we can expect to see even more innovative applications in the realms of synthetic biology, drug discovery, and beyond.

Fmoc-Glycine	2 Carbons
3-Amino-3-(2-Nitrophenyl) Propanoic Acid (ANP Linker)	3 Carbons
Fmoc-beta-Ala-OH	3 Carbons
4-Aminobutyric Acid (GABA) Fmoc-GABA-OH	4 Carbons
5-Aminovaleric Acid (Ava)	5 Carbons
Aminohexanoic Acid (Ahx)	6 Carbons
mini-PEG or AEEA Fmoc-NH-PEG2-CH2COOH	Length of Bonds: 9
mini-PEG2 or AEEP Fmoc-NH-PEG2-CH2CH2COOH	Length of Bonds: 10
AEEEA Fmoc-NH-PEG3-CH2COOH	Length of Bonds: 12
AEEEP, or PEG3 Fmoc-NH-PEG3-CH2CH2COOH	Length of Bonds: 13
AEEEEP, PEG4 Fmoc-NH-PEG4-CH2CH2COOH	Length of Bonds: 16
AEEEEEP, PEG5 Fmoc-NH-PEG5-CH2CH2COOH	Length of Bonds: 19

 

Cell-penetrating peptides (CPPs) have emerged as revolutionary tools in biomedical research and therapy, particularly for their ability to facilitate the transport of cargo molecules across cell membranes. Their application spans drug delivery to vaccine development, providing a non-invasive and efficient method for transporting therapeutic molecules into cells.

CPPs, consisting of short sequences of amino acids, are known for their amphipathic and/or cationic nature, which enables them to interact with cellular membranes effectively. These peptides can transport a wide range of bioactive substances, including proteins, DNA, RNA, and nanoparticles, into cells, thus opening up new avenues for therapeutic interventions. The ability of CPPs to deliver cargo molecules into cells without disrupting the membrane integrity is a critical feature that distinguishes them from other delivery vectors.

In the realm of nanotherapeutics, CPPs have shown great potential in enhancing the delivery of therapeutic molecules into cells, thereby overcoming the challenges posed by the physicochemical properties of the delivery vehicles and the biological barriers. Their applications have been extensively explored in cancer therapy, where they improve the intracellular delivery of nanocarriers, facilitating tumor imaging and targeted drug delivery. Moreover, CPPs are being used to address other medical challenges, such as evaluating atherosclerotic plaques and HIV therapy, demonstrating their versatility in medical applications​.

CPPs also play a crucial role in vaccine development, where they are used to enhance the stability and delivery of antigens to immune cells. By fusing antigens with CPPs, researchers have been able to improve the presentation of antigens by antigen-presenting cells (APCs), leading to the induction of both humoral and cellular immunity. This strategy has been applied to the development of vaccines against various infectious diseases, showing promise in improving the effectiveness of vaccines​.

The therapeutic applications of CPPs extend beyond drug delivery and vaccine development. They have been explored in diagnosing and treating a range of human diseases, from cancer to infectious diseases, demonstrating their potential in clinical applications. The ability of CPPs to deliver mRNA and other genetic materials into cells has opened new possibilities for gene therapy and the development of mRNA vaccines​.

Despite the promising applications of CPPs, challenges remain in understanding their cellular entry and internalization mechanisms. This knowledge gap limits their more comprehensive clinical application. However, ongoing research continues to unravel the complexities of CPP-mediated delivery, with studies employing advanced techniques to quantify and understand the intracellular trafficking of CPPs and their cargo​.

In summary, CPPs represent a versatile and powerful tool in the advancement of therapeutic strategies, offering a non-invasive, efficient, and potentially transformative approach to drug delivery and vaccine development. Their ability to cross biological barriers and deliver a wide range of bioactive molecules into cells holds significant promise for the future of medicine.